Last reviewed · How we verify
E. Coli Complicated Appendicitis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Merrem | Meropenem | Pfizer | meropenem | 1996-01-01 | ||
| Zosyn | TAZOBACTAM | Merck Sharp & Dohme B.V. | beta Lactamase Inhibitor | 1993-01-01 | ||
| Merrem | Merrem | National Institutes of Health Clinical Center (CC) | Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in E. Coli Complicated Appendicitis
- Merck Sharp & Dohme B.V. · 1 drug in E. Coli Complicated Appendicitis
- National Institutes of Health Clinical Center (CC) · 1 drug in E. Coli Complicated Appendicitis
- Pfizer · 1 drug in E. Coli Complicated Appendicitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in E. Coli Complicated Appendicitis:
- E. Coli Complicated Appendicitis treatment updates — RSS
- E. Coli Complicated Appendicitis treatment updates — Atom
- E. Coli Complicated Appendicitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). E. Coli Complicated Appendicitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-complicated-appendicitis. Accessed 2026-06-10.
Related
- E. Coli Complicated Appendicitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing